Evaluation of the Effects of Corticosteroids on Histamine Release by ex Vivo Cutaneous Microdialysis
Carol Courderot-Masuyer, Sophie Robin, Hélène Tauzin, Sylvain Harbon, Sophie Mac-Mary, Alexandre Guichard, Patrice Muret, Philippe Humbert
Bioexigence SARL, Espace Lafayette, 8 rue Alfred de Vigny, Besan?on, France.
Laboratory of Clinical and Toxicology Pharmacology, Jean Minjoz University Hospital, Besancon, France.
Plastic Surgery, 9 rue Klein, Saint Vincent Clinic, Besan?on, France.
Research and Clinicl Center on the Tegument (CERT); Clinical Investigation Center (CIC BT506), Department of Dermatology, Besan?on University Hospital, Besan?on, France.
Skinexigence SAS, immeuble Bioparc, 2 rue du Dr Paul Milleret, Besan?on, France.
University of Franche-Comté, Inserm U1098, SFR FED 4234 IBCT, Besan?on, France.
DOI: 10.4236/jcdsa.2013.33035   PDF   HTML     4,191 Downloads   5,793 Views   Citations

Abstract

The purpose of the study was to evaluate the effects of corticosteroids on histamine release and to compare their potency with the MacKenzie classification based on their vasoconstrictor effects. Thanks to ex Vivo cutaneous microdialysis, we studied histamine-induced release over a period of time on excised abdominal skin from women. Eight corticosteroids were topically applied with occlusive dressing onto the skin, above probes, before anti-IgE injection. Histamine levels were assessed by an EIA method. In order to compare the different corticosteroids, AUC was calculated allowing an estimation of the amount of released histamine for 60 min of ex vivo cutaneous microdialysis. Diflucortolone 0.1% and micronized betamethasone dipropionate 0.05% are considered as corticosteroids with high potency in MacKenzie classification. Betamethasone dipropionate associated with propylene glycol 0.05%, belongs to a stronger class in Mackenzie classification. Our results showed that the decrease in histamine release was more important with difluocortolone than with both of these corticosteroids. Therefore there was no correlation between the vasoconstrictor potency of topical corticosteroids and their ability to inhibit histamine release.

Share and Cite:

C. Courderot-Masuyer, S. Robin, H. Tauzin, S. Harbon, S. Mac-Mary, A. Guichard, P. Muret and P. Humbert, "Evaluation of the Effects of Corticosteroids on Histamine Release by ex Vivo Cutaneous Microdialysis," Journal of Cosmetics, Dermatological Sciences and Applications, Vol. 3 No. 3, 2013, pp. 228-233. doi: 10.4236/jcdsa.2013.33035.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] A. W. MacKenzie and R. B. Stoughton, “A Method for Comparing Percutaneous Absorption of Steroids,” Archives of Dermatology, Vol. 86, No. 11, 1962, pp. 608-610. doi:10.1001/archderm.1962. 01590110044005
[2] A. W. McKenzie, “Percutaneous Absorption of Steroids,” Archives of Dermatology, Vol. 86, No. 11, 1962, pp. 611-614. doi:10.1001/archderm.1962.01590110047006
[3] S. Wiedersberg, C. S. Leopold and R. H. Guy, “Bioavailability and Bioequivalence of Topical Glucocorticoids,” European Journal of Pharmaceutics and Biopharmaceutics, Vol. 68, No. 3, 2008, pp. 453-466. doi:10.1016/j.ejpb.2007.08.007
[4] Y. Narkar, “Bioequivalence for Topical Products—An Update,” Pharmaceutical Research, Vol. 27, No. 12, 2010, pp. 2590-2601. doi:10.1007/s11095-010-0250-3
[5] Organisation for Economic Co-operation and Development (OECD), “Test Guideline 427: In Vitro Method,” Paris, 2004.
[6] T. J. Franz, P. A. Lehman and S. G. Raney, “Use of Excised Human Skin to Assess the Bioequivalence of Topical Products,” Skin Pharmacology and Physiology, Vol. 22, No. 5, 2009, pp. 276-286. doi:10.1159/ 000235828
[7] A. Le Quellec, S. Dupin, P. Genissel, S. Saivin, B. Marchand and J. P. M. Houin, “Microdialysis Probes Calibration: Gradient and Tissue Dependent Changes in No Flux and Reverse Dialysis Methods,” Journal of Pharmacoogical and Toxicological Methods, Vol. 33, No. 1, 1995, pp. 11-16. doi:10.1016/1056-8719(94)00049-A
[8] N. Leveque, S. Makki, J. Hadgraft and P. Humbert, “Comparison of Franz Cells and Microdialysis for Assessing Salicylic Penetration through Human Skin,” International Journal of Pharmaceutics, Vol. 269, No. 2, 2004, pp. 323-328. doi:10.1016/j.ijpharm.2003.09.012
[9] I. Brody, “Mast Cell Degranulation in the Evolution of Acute Eruptive Guttate Psoriasis Vulgaris,” Journal of Investigative Dermatology, Vol. 82, No. 5, 1984, pp. 460464. doi:10.1111/1523-1747.ep12260955
[10] A. L. Krogstad, G. Lonnroth, B. F. G. Larson and B. G. Wallin, “Nerve-Induced Histamine Release Is of Little Importance in Psoriatic Skin,” British Journal of Dermatology, Vol. 139, No. 5, 1998, pp. 403-409. doi:10.1046/j.1365-2133.1998.02402.x
[11] T. Ishizaka, D. H. Conrad, T. F. Huff, D. D. Metcalfe, R. L. Stevens and R. A. Lewis, “Unique Features of Human Basophilic Granulocytes Developed in in Vitro Culture,” International Archives of Allergy and Applied Immunology, Vol. 77, No. 1-2, 1985, pp. 137-143. doi:10.1159/000233768
[12] L. J. Petersen, K. Brasso, M. Pryds and P. S. Skov, “Histamine Release in Intact Human Skin by Monocyte Chemoattractant Factor-1, RANTES, Macrophage Inflammatory Protein-1 Alpha, Stem Cell Factor, Anti-IgE, and Codeine as Determined by an ex Vivo Skin Microdialysis Technique,” Journal of Allergy and Clinical Immunology, Vol. 98, No. 4, 1996, pp. 790-796. doi:10.1016/S0091-6749(96)70128-8
[13] L. K. Pershing, B. S. Silver, G. G. Krueger, V. P. Shah and J. P. Skelly, “Feasibility of Measuring the Bioavailability of Topical Betamethasone Dipropionate in Commercial Formulations Using Drug Content in Skin and a Blanching Bioassay,” Pharmaceutical Research, Vol. 9, No. 1, 1992, pp. 45-51. doi:10.1023/ A:1018975626210
[14] B. W. Barry and R. Woodford, “Activity and Bioavailability of Topical Corticosteroids: In Vivo/In Vitro Correlations for the Vasoconstrictor Test,” Journal of Clinical Pharmacology, Vol. 3, No. 1, 1978, pp. 43-65.
[15] K. H. Burdick, “Corticosteroid Bioavailability Assays: Correlation with a Clinical Study,” Acta Dermato-Venereologica: Supplement (Stockholm), Vol. 52, No. 67, 1971, pp. 19-23.
[16] B. W. Barry, “Bioavailability of Topical Steroids,” Dermatologica, Vol. 152, Suppl. 1, 1976, pp. 47-65. doi:10.1159/000257866
[17] G. L. Coleman, I. Kanfer and J. M. Haigh, “Comparative Blanching Activities of Proprietary Diflucortolone Valerate Topical Preparations,” Dermatologica, Vol. 156, No. 4, 1978, pp. 224-230. doi:10.1159/ 000250920
[18] E. Meyer, A. D. Magnus, J. M. Haigh and I. Kanfer, “Comparison of the Blanching Activities of Dermovate, Betnovate and Eumovate Creams and Ointments,” International Journal of Pharmaceutics, Vol. 41, No. 1, 1988, pp. 63-66. doi:10.1016/0378-5173(88)90136-6
[19] E. W. Smith, E. Meyer, J. M. Haigh and H. I. Maibach, “The Human Skin Blanching Assay as an Indicator of Topical Corticosteroid Bioavailability and Potency: An Update,” In: R. L. Bronaugh and H. I. Maibach, Eds., Percutaneous Absorption: Mechanisms, Methodology and Drug Delivery, 2nd Edition, Marcel Dekker, Inc., New York, 1989, pp. 443-460.
[20] J. M. Haigh and L. Kanfer, “Assessment of Topical Corticosteroid Preparations: The Human Skin Blanching Assay,” International Journal of Pharmaceutics, Vol. 19, No. 3, 1984, pp. 245-262. doi:10.1016/ 0378-5173(84)90055-3

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.